Targeting PAK1 is effective against cutaneous squamous cell carcinoma in a syngenic mouse model
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of...
Saved in:
Published in | Cancer Science Vol. 115; no. 8; pp. 2839 - 2845 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley
01.08.2024
John Wiley & Sons, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC.
PAK1 inhibitor treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. |
---|---|
AbstractList | By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS-PAK1-1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA-induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS-PAK1-1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA-sequencing analysis on the engrafted tumors indicates that NVS-PAK1-1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan-keratin-positive regions and potentially elevated infiltration of CD8-positive immune cells in NVS-PAK1-1-treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC. By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC. PAK1 inhibitor treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC. By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS-PAK1-1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA-induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS-PAK1-1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA-sequencing analysis on the engrafted tumors indicates that NVS-PAK1-1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan-keratin-positive regions and potentially elevated infiltration of CD8-positive immune cells in NVS-PAK1-1-treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC.By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS-PAK1-1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA-induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS-PAK1-1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA-sequencing analysis on the engrafted tumors indicates that NVS-PAK1-1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan-keratin-positive regions and potentially elevated infiltration of CD8-positive immune cells in NVS-PAK1-1-treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC. By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC. |
Author | Takao Morinaga Keisuke Otoyama Yosuke Togashi Kazuhiro Okumura Sora Tanaka Yuichi Wakabayashi Megumi Saito Yurika Tokunaga Eriko Isogai Masahito Kawazu Yoshinori Hasegawa |
Author_xml | – sequence: 1 givenname: Kazuhiro surname: Okumura fullname: Okumura, Kazuhiro organization: Chiba Cancer Center Research Institute – sequence: 2 givenname: Takao surname: Morinaga fullname: Morinaga, Takao organization: Chiba Cancer Center Research Institute – sequence: 3 givenname: Megumi surname: Saito fullname: Saito, Megumi organization: Chiba Cancer Center Research Institute – sequence: 4 givenname: Yurika surname: Tokunaga fullname: Tokunaga, Yurika organization: Chiba Cancer Center Research Institute – sequence: 5 givenname: Keisuke surname: Otoyama fullname: Otoyama, Keisuke organization: Chiba Cancer Center Research Institute – sequence: 6 givenname: Sora surname: Tanaka fullname: Tanaka, Sora organization: Chiba Cancer Center Research Institute – sequence: 7 givenname: Eriko surname: Isogai fullname: Isogai, Eriko organization: Chiba Cancer Center Research Institute – sequence: 8 givenname: Masahito surname: Kawazu fullname: Kawazu, Masahito organization: Chiba Cancer Center Research Institute – sequence: 9 givenname: Yosuke orcidid: 0000-0001-9910-0164 surname: Togashi fullname: Togashi, Yosuke organization: Okayama University – sequence: 10 givenname: Yoshinori surname: Hasegawa fullname: Hasegawa, Yoshinori organization: Kazusa DNA Research Institute – sequence: 11 givenname: Yuichi orcidid: 0000-0002-8861-2954 surname: Wakabayashi fullname: Wakabayashi, Yuichi email: yuichi_wakabayashi@chiba‐cc.jp organization: Chiba Cancer Center Research Institute |
BackLink | https://cir.nii.ac.jp/crid/1871429166527071488$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/38898727$$D View this record in MEDLINE/PubMed |
BookMark | eNp10Utr3DAQAGBREpo0zaF_oAjaQ3twopct6bgsfZFACk3PYiyNFxVbTiy7Zf99tXHSQyE6jObwzTDMvCJHaUxIyBvOLnh5lx7yBW-Eal6QUy6VrTRjzdFDrivLpDgh5znHltVGWaGMeElOpDHWaKFPibuFaYdzTDv6fXPFacwUuw79HH8jhR3ElGfqlxkSjkum-X6B4ZB47HvqYfIxjQPQmCjQvE87TNHTg8ASA_avyXEHfcbzx_-M_Pz86Xb7tbq--fJtu7muvFKyqbpgulYw3YCyEBBNLWzHQm2CbhlqjoyBVQw850pCkAEBBWvrOmiDoePyjHxY-95N4_2CeXZDzIch18GdZJoZUVtpC333H_01LlMq0xVlmRYNt3VRbx_V0g4Y3N0UB5j27ml1BXxcgZ_GnCfs_hHO3OEyrlzGPVym2MvV_ok97p-Hbrv58VTxfq1IMbqy5BK50VwJy5umFpqV3Bj5F6pHmEg |
Cites_doi | 10.1158/0008-5472.CAN-04-3480 10.1016/j.jid.2018.12.027 10.1021/acs.jmedchem.2c00756 10.1038/s41598-017-11561-x 10.1186/s12885-017-3432-0 10.3390/cells12192373 10.1016/j.jid.2024.01.021 10.3389/fchem.2021.707317 10.1093/carcin/bgg067 10.1093/carcin/bgs250 10.1016/j.jid.2022.02.009 10.1038/s41388-020-1323-3 10.1021/acsmedchemlett.5b00102 10.1007/s10555-008-9168-1 10.1016/j.canlet.2019.12.020 10.1093/hmg/ddab106 10.1042/BST20160134 |
ContentType | Journal Article |
Copyright | 2024 The Author(s). published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Author(s). published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | RYH 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1111/cas.16246 |
DatabaseName | CiNii Complete Wiley-Blackwell Open Access Titles CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1349-7006 |
EndPage | 2845 |
ExternalDocumentID | 38898727 10_1111_cas_16246 CAS16246 |
Genre | researchArticle Journal Article |
GrantInformation_xml | – fundername: Takeda Foundation – fundername: Japan Society for the Promotion of Science funderid: JP19K07494; JP22K07012 – fundername: Japan Society for the Promotion of Science grantid: JP22K07012 – fundername: Japan Society for the Promotion of Science grantid: JP19K07494 |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 1OC 24P 29B 36B 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 5GY 5HH 5LA 5VS 66C 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 88E 8FE 8FH 8FI 8FJ 8UM 930 A01 A03 AAFWJ AAHHS AAZKR ABCQN ABUWG ACCFJ ACCMX ACXQS ADBBV ADKYN ADPDF ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFKRA AFPKN AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BHPHI BY8 CCPQU CS3 D-6 D-7 D-E D-F DR2 DU5 E3Z EBS EMB EMOBN EX3 F00 F01 F04 F5P FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE HZI HZ~ IAO IHR ITC IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 M1P M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PHGZM PHGZT PIMPY PROAC PSQYO Q11 ROL RPM RX1 RYH SJN SV3 TEORI UB1 UKHRP W8V WOW WQJ WXI XG1 ~IA ~WT .55 .Y3 2WC 31~ 3O- 53G 7.U ABEML ACSCC AFFNX AFZJQ BFHJK CAG COF DIK EJD FIJ GODZA HF~ HOLLA IPNFZ LW6 SUPJJ WIN WRC X7M ZXP AAYXX CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c4436-fd8fb2076a49adee8529f0d58d7b0e71e00a940ac1143ad3deae20b55d78edf13 |
IEDL.DBID | DR2 |
ISSN | 1347-9032 1349-7006 |
IngestDate | Tue Aug 05 09:22:57 EDT 2025 Wed Aug 13 01:33:21 EDT 2025 Mon Jul 21 05:55:50 EDT 2025 Tue Jul 01 01:31:19 EDT 2025 Wed Jan 22 17:15:10 EST 2025 Thu Jun 26 23:30:36 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | PAK1 inhibitor mouse DMBA/TPA syngenic model squamous cell carcinoma |
Language | English |
License | Attribution-NonCommercial 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4436-fd8fb2076a49adee8529f0d58d7b0e71e00a940ac1143ad3deae20b55d78edf13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-9910-0164 0000-0002-8861-2954 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.16246 |
PMID | 38898727 |
PQID | 3090726195 |
PQPubID | 4378882 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_3070825939 proquest_journals_3090726195 pubmed_primary_38898727 crossref_primary_10_1111_cas_16246 wiley_primary_10_1111_cas_16246_CAS16246 nii_cinii_1871429166527071488 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | August 2024 |
PublicationDateYYYYMMDD | 2024-08-01 |
PublicationDate_xml | – month: 08 year: 2024 text: August 2024 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Tokyo |
PublicationTitle | Cancer Science |
PublicationTitleAlternate | Cancer Sci |
PublicationYear | 2024 |
Publisher | Wiley John Wiley & Sons, Inc |
Publisher_xml | – name: Wiley – name: John Wiley & Sons, Inc |
References | 2021; 9 2017; 7 2022; 142 2015; 6 2023; 12 2017; 17 2020; 472 2017; 45 2020; 39 2003; 24 2005; 65 2019; 139 2022; 65 2024 2021; 30 2012; 33 2009; 28 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 |
References_xml | – year: 2024 article-title: Deletion of Pak1 in CD11c positive cells resistance to mouse skin carcinogenesis publication-title: J Invest Dermatol – volume: 139 start-page: 1459 issue: 7 year: 2019 end-page: 1469 article-title: A polymorphic variant in p19Arf confers resistance to chemically induced skin tumors by activating the p53 pathway publication-title: J Invest Dermatol – volume: 17 start-page: 431 issue: 1 year: 2017 article-title: Depletion of p21‐activated kinase 1 up‐regulates the immune system of APC∆14/+ mice and inhibits intestinal tumorigenesis publication-title: BMC Cancer – volume: 65 start-page: 15627 issue: 23 year: 2022 end-page: 15641 article-title: Development and utility of a PAK1‐selective degrader publication-title: J Med Chem – volume: 45 start-page: 79 issue: 1 year: 2017 end-page: 88 article-title: Targeting PAK1 publication-title: Biochem Soc Trans – volume: 39 start-page: 4756 issue: 24 year: 2020 end-page: 4769 article-title: Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis publication-title: Oncogene – volume: 142 start-page: 2323 issue: 9 year: 2022 end-page: 2333.e12 article-title: Functional polymorphism in Pak1‐3' untranslated region alters skin tumor susceptibility by alternative polyadenylation publication-title: J Invest Dermatol – volume: 9 year: 2021 article-title: E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points publication-title: Front Chem – volume: 24 start-page: 1159 issue: 7 year: 2003 end-page: 1165 article-title: Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis publication-title: Carcinogenesis – volume: 33 start-page: 2260 issue: 11 year: 2012 end-page: 2268 article-title: Independent genetic control of early and late stages of chemically induced skin tumors in a cross of a Japanese wild‐derived inbred mouse strain, MSM/Ms publication-title: Carcinogenesis – volume: 7 issue: 1 year: 2017 article-title: The parathyroid hormone regulates skin tumour susceptibility in mice publication-title: Sci Rep – volume: 65 start-page: 3179 issue: 8 year: 2005 end-page: 3184 article-title: Pak1 phosphorylation of snail, a master regulator of epithelial‐to‐mesenchyme transition, modulates snail's subcellular localization and functions publication-title: Cancer Res – volume: 28 start-page: 51 issue: 1–2 year: 2009 end-page: 63 article-title: Pak protein kinases and their role in cancer publication-title: Cancer Metastasis Rev – volume: 6 start-page: 776 issue: 7 year: 2015 end-page: 781 article-title: Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor publication-title: ACS Med Chem Lett – volume: 30 start-page: 1607 issue: 17 year: 2021 end-page: 1617 article-title: PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of neurofibromatosis type 2 (NF2) publication-title: Hum Mol Genet – volume: 472 start-page: 8 year: 2020 end-page: 18 article-title: Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti‐tumour immunity through down‐regulation of PD‐L1 publication-title: Cancer Lett – volume: 12 start-page: 2373 issue: 19 year: 2023 article-title: PAK1 and therapy resistance in melanoma publication-title: Cells – ident: e_1_2_10_13_1 doi: 10.1158/0008-5472.CAN-04-3480 – ident: e_1_2_10_10_1 doi: 10.1016/j.jid.2018.12.027 – ident: e_1_2_10_18_1 doi: 10.1021/acs.jmedchem.2c00756 – ident: e_1_2_10_9_1 doi: 10.1038/s41598-017-11561-x – ident: e_1_2_10_14_1 doi: 10.1186/s12885-017-3432-0 – ident: e_1_2_10_16_1 doi: 10.3390/cells12192373 – ident: e_1_2_10_4_1 doi: 10.1016/j.jid.2024.01.021 – ident: e_1_2_10_17_1 doi: 10.3389/fchem.2021.707317 – ident: e_1_2_10_12_1 doi: 10.1093/carcin/bgg067 – ident: e_1_2_10_8_1 doi: 10.1093/carcin/bgs250 – ident: e_1_2_10_11_1 doi: 10.1016/j.jid.2022.02.009 – ident: e_1_2_10_3_1 doi: 10.1038/s41388-020-1323-3 – ident: e_1_2_10_5_1 doi: 10.1021/acsmedchemlett.5b00102 – ident: e_1_2_10_2_1 doi: 10.1007/s10555-008-9168-1 – ident: e_1_2_10_15_1 doi: 10.1016/j.canlet.2019.12.020 – ident: e_1_2_10_7_1 doi: 10.1093/hmg/ddab106 – ident: e_1_2_10_6_1 doi: 10.1042/BST20160134 |
SSID | ssib058492482 ssib002224741 ssib048395060 ssib002484371 ssj0036494 ssib050729863 |
Score | 2.4315743 |
Snippet | By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1... By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1... |
SourceID | proquest pubmed crossref wiley nii |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2839 |
SubjectTerms | 9,10-Dimethyl-1,2-benzanthracene - toxicity Allosteric properties Animals Antibodies Carcinogenesis Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - pathology CD8 antigen CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - metabolism Cell differentiation Cell Differentiation - drug effects Cell growth Cell Line, Tumor Cell Proliferation - drug effects Disease Models, Animal DMBA/TPA Female Genes Genetic analysis Immune response Keratin Kinases Metastases Mice Morphology mouse p21-Activated Kinases - antagonists & inhibitors p21-Activated Kinases - genetics p21-Activated Kinases - metabolism PAK1 inhibitor Phosphorylation Sequence analysis Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - metabolism Skin Neoplasms - pathology Squamous cell carcinoma Syngeneic grafts syngenic model Tetradecanoylphorbol Acetate Tumors |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Na9VAEB9sBfEi1s9oW1bx4CW43x8neZSWolQEW3i3sMluJIfmtea9g_-9M0neU0F7CYHkMJnZzPx-u7P7A3jXJptkzKbkPqpSixTKuhVIXK1rvHEt8iIiihdf7PmV_rQ0y3nCbZjbKrc5cUzUadXQHPkHxZHGEdw3H29uS1KNotXVWUJjD-7T0WXU0uWWO8KlrA6TqK12ZeBKzicLUScPCYoJKwn3_lGP9vqu-xfU_Bu5jqXn7DE8mjEjW0xBPoB7uX8CDy7mVfGnUF2O7dxYhNjXxWfBuoFNbRqYyVj8jtx_WLNmgzAwI89nw-0mEuFnNGnPGhIT6lfXkXU9i2z4SZutuobRG5mNQjnP4Ors9PLkvJyFE8pGa2XLNvm2ltzZqENMOXsjQ8uT8cnVPDuROY9B89ggGVIxqZRjlrw2JjmfUyvUc9jvV31-CaxWKqsoai9y0Cb5iPAgONlkZVSwPhTwduu-6mY6H6Pa8gr0cTX6uIAjdGyFX4NXgRQNi6Cw1khH26e8L-Bw6_Jq_oWG6nfAC3ize4yDn5wzOayihIUUF00q4MUUqp0VyvvgEZ0V8H6M3f_Nq04W38abV3fb8RoeSoQ0U_vfIeyvf2zyEUKSdX08jrtfKh7aeA priority: 102 providerName: ProQuest |
Title | Targeting PAK1 is effective against cutaneous squamous cell carcinoma in a syngenic mouse model |
URI | https://cir.nii.ac.jp/crid/1871429166527071488 https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.16246 https://www.ncbi.nlm.nih.gov/pubmed/38898727 https://www.proquest.com/docview/3090726195 https://www.proquest.com/docview/3070825939 |
Volume | 115 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9UwEB52VxBfvF-qu4coPvjSJWnu-HRcdlmUXQ7rLpwHoaRNKkXsUXv6oL_eSW-4oiC-lEJTmMxkku9LJjMALyuvfOaCTKlxPBXM27SoGBJXpUsjdYW8KBLFs3N1eiXeruV6B15Pd2GG_BDzhlv0jH6-jg7uivYXJ48lwZjKREy3HWO1IiC6mFNHcSXsUNBW6NRSno1ZhWIUz_zntbVot6nrP8HM66i1X3ZO7sCHSeAh2uTTYbctDssfv-Vy_M8e3YXbIxwly2H83IOd0NyHm2fjgfsDyC_7SHFc38hq-Y6RuiVDBAhOksR9dDWiS1J2iDDDpmtJ-7VzcS-BxPMAUsY6Rc3msyN1Qxxpv8d7XHVJYotA-ho8D-Hq5Pjy6DQdazKkpRBcpZU3VZFRrZywzodgZGYr6qXxuqBBs0Cps4K6EnkWd5774EJGCym9NsFXjD-CvWbThCdACs4Dd6wwLFghvXGIPKzOysAlt8rYBF5M1sm_DKk38omyoKryXlUJHKDdcuwNPhmyP1xfmVIy0_FmljEJ7E8WzUfvbHNOLdWROsoEns-f0a-icgaF5XEuRPaMIiXweBgJsxTcGGsQ-CXwqrfn38XLj5bv-5en_970GdzKEDkNUYb7sLf91oUDRD7bYgG7mVjhU6_1Am68OT5fXSz6XYRFP_h_AtVr_rk |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB71IQGXimeb0oJBIHGJ8CNO7ANCS2m1ZburCrZSb8aJHZRDs23TFeqf4jcyzqOABNx6iSIlipzP45nvs8cegFelSx23XsZUWREnzOk4LxkK1zQrlMxK1EVBKE5n6fgk-XQqT1fgx7AXJqRVDj6xddRuUYQ58reCoowLdF--P7-IQ9WosLo6lNDozGLir7-jZGveHX7E_n3N-cH-fG8c91UF4iJJRBqXTpU5R_luE22d90pyXVInlcty6jPmKbU6obZApSCsE85bz2kupcuUdyUT-N1VWMdPUXQE6x_2Z8efB98v0kR3ZXSTLNZU8P4so5A7FEqYsZQHpv1bBFytq-pv5PZPrtwGu4P7sNGzVDLqzOoBrPj6IdyZ9uvwj8DM2wRyDHvkeDRhpGpIlxiCvpPYb7ZC0kmKJRJPv1g2pLlY2jDFQMIyASlC-aJ6cWZJVRNLmuuwvasqSHjDk7Y0z2M4uRVQn8Bavaj9FpBcCC8syxXzOpFOWSQkOuOFF1LoVOkIXg7wmfPuRA4zKBnE2LQYR7CLwBr8G7wyFIUYdlmaSp6FDVtKRbAzQG76QduYXyYWwYubxzjcAjgdYCa4SBTV2KQINruuummFUEor5IMRvGn77t_NM3ujL-3N9v_b8RzujufTI3N0OJs8hXscCVWXfLgDa1eXS7-LhOgqf9ZbIYGvt234PwEbqhnS |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB61Raq4IN4NbcEgkLhEjV-xfUBo1bJqWVpVopX2ZpzYQTmQbZuuUP8av45xHgtIwK2XKFKiyPk8nvk-e-wBeF353DMXZJppx1NBvUmLiqJwzVWppapQF0WheHySH56Lj3M5X4Mf416YmFY5-sTOUftFGefI93iGMi7SfblXDWkRpwfT9xeXaawgFVdax3IavYnMws13lG_tu6MD7Os3jE0_nO0fpkOFgbQUgudp5XVVMJTyThjnQ9CSmSrzUntVZEHRkGXOiMyVqBq489wHF1hWSOmVDr6iHL-7DncUlzSOMTVfiT2eC9MX1BUqNRlnw6lGMYsoFjOjOYuc-7dYuN7U9d9o7p-suQt70_twb-CrZNIb2ANYC81D2DweVuQfgT3rUskxAJLTyYySuiV9igh6UeK-uhrpJymXSEHDYtmS9nLp4mQDiQsGpIyFjJrFN0fqhjjS3sSNXnVJ4huBdEV6HsP5rUD6BDaaRRO2gBScB-5ooWkwQnrtkJoYxcrAJTe5Ngm8GuGzF_3ZHHbUNIix7TBOYBeBtfg3eKUoDzEA0zyXTMWtW1onsDNCbofh29pfxpbAy9VjHHgRnB4wG50lymtsUgJP-65atYJrbTQywwTedn337-bZ_cnn7ubZ_9vxAjbR3O2no5PZNtxlyKz6LMQd2Li-WoZdZEbXxfPOBAl8uW2b_wlduxyi |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+PAK1+is+effective+against+cutaneous+squamous+cell+carcinoma+in+a+syngenic+mouse+model&rft.jtitle=Cancer+science&rft.au=Okumura%2C+Kazuhiro&rft.au=Morinaga%2C+Takao&rft.au=Saito%2C+Megumi&rft.au=Tokunaga%2C+Yurika&rft.date=2024-08-01&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=115&rft.issue=8&rft.spage=2839&rft.epage=2845&rft_id=info:doi/10.1111%2Fcas.16246&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_cas_16246 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |